Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Iodohippurate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodohippurate SCHEMBL29576793 | 1.00 | KMT2A (0.50) | KMT2AMEN1TDP1SIGMAR1TSHR | |
| Iodohippurate SCHEMBL5915003 | 0.97 | KMT2A (0.50) | KMT2AMEN1TDP1SIGMAR1TSHR | |
| Iodohippurate SCHEMBL589803 | 0.82 | KMT2A (0.58) | KMT2AMEN1TDP1SIGMAR1ABL1 | |
| Iodohippurate SCHEMBL29959499 | 0.82 | KMT2A (0.58) | KMT2AMEN1TDP1SIGMAR1ABL1 | |
| Iodohippurate SCHEMBL5915006 | 0.81 | KMT2A (0.56) | KMT2AMEN1TDP1SIGMAR1ABL1 | |
| Iodohippurate SCHEMBL2142713 | 0.81 | KMT2A (0.56) | KMT2AMEN1TDP1SIGMAR1ABL1 | |
| SCHEMBL8814831 | 0.81 | KMT2A (0.51) | KMT2AMEN1TDP1SIGMAR1TSHR | |
| SCHEMBL11325406 | 0.81 | KMT2A (0.51) | KMT2AMEN1TDP1SIGMAR1TSHR | |
| Iodohippurate SCHEMBL9860635 | 0.81 | KMT2A (0.56) | KMT2AMEN1TDP1SIGMAR1ABL1 | |
| Salicyluric Acid SCHEMBL29366327 | 0.81 | KDM4E (0.55) | KMT2AMEN1TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117865933-A | Stilbene photochromic material containing dibenzothiophene and preparation method thereof | 上海陕煤高新技术研究院有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117865917-A | Photochromic aggregation-state-dependent triarylethylene material and preparation method thereof | 上海陕煤高新技术研究院有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-115611896-A | Compound containing tetralone or tetrahydropyridopyrimidone skeleton and preparation method and pharmaceutical application thereof | 中国药科大学 | 2023-01-17 | — | — | CN | claimed |
| EP-2706881-B1 | RADIATION PROTECTION DEVICE AND METHODS THEREOF | STEMRAD LTD (IL) | 2018-07-25 | — | — | EP | claimed |
| US-20110052503-A1 | BIODEGRADABLE CONTRAST AGENTS | IOPHARMA TECHNOLOGIES AB (SE) | 2011-03-03 | — | — | US | claimed |
| EP-2237800-A2 | BIODEGRADABLE CONTRAST AGENTS | Iopharma Technologies Ab (SE) | 2010-10-13 | — | — | EP | claimed |
| WO-2009081169-A2 | BIODEGRADABLE CONTRAST AGENTS | IOPHARMA TECHNOLOGIES AB (SE) | 2009-07-02 | — | — | WO | claimed |
| EP-2035007-A1 | USE OF ADENOSINE A1 ANTAGONIST IN RADIOCONTRAST MEDIA INDUCED NEPHROPATHY | Solvay Pharmaceuticals GmbH (DE) | 2009-03-18 | — | — | EP | claimed |
| US-20080045551-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN ADENOSINE A1 ANTAGONIST AND A RADIOCONTRAST MEDIA | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-20080027082-A1 | USE OF ADENOSINE A1 ANTAGONISTS IN RADIOCONTRAST MEDIA INDUCED NEPHROPATHY | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-01-31 | — | — | US | claimed |
| WO-2007147809-A1 | USE OF ADENOSINE A1 ANTAGONIST IN RADIOCONTRAST MEDIA INDUCED NEPHROPATHY | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-12-27 | — | — | WO | claimed |
| EP-1870093-A1 | Pharmaceutical combination comprising adenosine A1 receptor antagonists and radiocontrast media | Solvay Pharmaceuticals GmbH (DE) | 2007-12-26 | — | — | EP | claimed |
| EP-4747233-A2 | COMPOUNDS, COMPOSITIONS CONTAINING COMPOUNDS, AND METHODS OF MANUFACTURING RESIST MEMBRANES | Merck Patent GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20260014207-A1 | METHODS AND COMPOSITIONS FOR TREATING PERINATAL HYPOXIC-ISCHEMIC BRAIN INJURY | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2026-01-15 | — | — | US | disclosed |
| EP-0165630-A2 | Method of preparing a chlorinated, brominated, radiobrominated, iodinated and/or radioiodinated, aromatic or heteroaromatic compound, as well as a kit for preparing a diagnostic composition on the basis of this compound | MALLINCKRODT, INC.(a Missouri corporation) (US) | 1985-12-27 | — | — | EP | disclosed |
| EP-0113135-A2 | Radiolabelled metallocene derivatives | Mallinckrodt Diagnostica (Holland) B.V. (NL) | 1984-07-11 | — | — | EP | disclosed |
| US-4307072-A | X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4268495-A | A PROLAMINE AND A SOLVENT | ETHICON, INC. (US) | 1981-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | KMT2A 1584/4885MEN1 1288/4885TDP1 3420/4885 |
| US-20080027082-A1 | USE OF ADENOSINE A1 ANTAGONISTS IN RADIOCONTRAST MEDIA INDUCED NEPHROPATHY | ADORA1, ADORA2A, ADORA3 | KMT2A 1615/4885MEN1 762/4885TDP1 998/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | KMT2A 1769/4885MEN1 1342/4885TDP1 3681/4885 |
| US-20260014207-A1 | METHODS AND COMPOSITIONS FOR TREATING PERINATAL HYPOXIC-ISCHEMIC BRAIN INJURY | S100B, HTRA2, HTR2B | KMT2A 2502/4885MEN1 4580/4885TDP1 2251/4885 |
| US-20110052503-A1 | BIODEGRADABLE CONTRAST AGENTS | CNDP2, RXFP1, RXFP3 | KMT2A 2000/4885MEN1 550/4885TDP1 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.